Found: 15
Select item for more details and to access through your institution.
Phase 1 study to evaluate the effects of rifampin on pharmacokinetics of pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 5, p. 1042, doi. 10.1007/s10637-022-01286-8
- By:
- Publication type:
- Article
Phase I study assessing the mass balance, pharmacokinetics, and excretion of [14C]-pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 2, p. 488, doi. 10.1007/s10637-020-01017-x
- By:
- Publication type:
- Article
Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2019, v. 37, n. 1, p. 87, doi. 10.1007/s10637-018-0610-0
- By:
- Publication type:
- Article
Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Optimized virologic response in hepatitis C virus genotype 4 with peginterferon-alpha2a and ribavirin.
- Published in:
- 2004
- By:
- Publication type:
- letter
Infection with hepatitis C virus genotype 4 is associated with a poor response to interferon-alpha.
- Published in:
- 2001
- By:
- Publication type:
- letter
Pevonedistat in East Asian patients with acute myeloid leukemia or myelodysplastic syndromes: a phase 1/1b study to evaluate safety, pharmacokinetics and activity as a single agent and in combination with azacitidine.
- Published in:
- Journal of Hematology & Oncology, 2022, v. 15, n. 1, p. 1, doi. 10.1186/s13045-022-01264-w
- By:
- Publication type:
- Article
Randomized Phase II Trial of Sapanisertib ± TAK-117 vs. Everolimus in Patients With Advanced Renal Cell Carcinoma After VEGF-Targeted Therapy.
- Published in:
- Oncologist, 2022, v. 27, n. 12, p. 1048, doi. 10.1093/oncolo/oyac192
- By:
- Publication type:
- Article
Pevonedistat ( MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study.
- Published in:
- British Journal of Haematology, 2015, v. 169, n. 4, p. 534, doi. 10.1111/bjh.13323
- By:
- Publication type:
- Article
Population pharmacokinetics of pevonedistat alone or in combination with standard of care in patients with solid tumours or haematological malignancies.
- Published in:
- British Journal of Clinical Pharmacology, 2019, v. 85, n. 11, p. 2568, doi. 10.1111/bcp.14078
- By:
- Publication type:
- Article
Effect of CYP3A inhibitors on the pharmacokinetics of pevonedistat in patients with advanced solid tumours.
- Published in:
- British Journal of Clinical Pharmacology, 2019, v. 85, n. 7, p. 1464, doi. 10.1111/bcp.13915
- By:
- Publication type:
- Article
Monthly oral ibandronate is effective and well tolerated after 3 years: the MOBILE long-term extension.
- Published in:
- Clinical Rheumatology, 2008, v. 27, n. 8, p. 955, doi. 10.1007/s10067-007-0824-6
- By:
- Publication type:
- Article
Asia‐inclusive global development of pevonedistat: Clinical pharmacology and translational research enabling a phase 3 multiregional clinical trial.
- Published in:
- CTS: Clinical & Translational Science, 2021, v. 14, n. 3, p. 1069, doi. 10.1111/cts.12972
- By:
- Publication type:
- Article
Correction to: A Phase 1 Study of Sapanisertib (TAK-228) in East Asian Patients with Advanced Nonhematological Malignancies.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
A Phase 1 Study of Sapanisertib (TAK-228) in East Asian Patients with Advanced Nonhematological Malignancies.
- Published in:
- 2022
- By:
- Publication type:
- journal article